
Seneca Biopharma, Inc. EBITDA 2011-2026 | SNCA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Seneca Biopharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -10.6 M | -8.49 M | -8.07 M | -13 M | -20.3 M | -18.8 M | -17.1 M | -12.3 M | -9.95 M | -12.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.07 M | -20.3 M | -13.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 8.41 | 4.73 % | $ 230 M | ||
|
Ardelyx
ARDX
|
-37.9 M | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
argenx SE
ARGX
|
-349 M | $ 752.35 | 0.79 % | $ 25 B | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 23.83 | 0.85 % | $ 3.03 B | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
BioCardia
BCDA
|
-8.25 M | $ 1.2 | -0.04 % | $ 8 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
-1.3 M | $ 9.6 | 6.37 % | $ 1.98 B | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-679 M | $ 9.48 | -3.27 % | $ 613 M | ||
|
BioVie
BIVI
|
-17.8 M | $ 1.45 | 2.09 % | $ 2.14 M | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
BioMarin Pharmaceutical
BMRN
|
489 M | $ 56.49 | 1.78 % | $ 10.8 B | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 92.3 | 1.23 % | $ 27.2 B | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-51.4 M | $ 3.04 | 1.54 % | $ 259 M | ||
|
BioXcel Therapeutics
BTAI
|
-50.2 M | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 4.54 | 9.54 % | $ 683 M | ||
|
Cabaletta Bio
CABA
|
-171 M | $ 3.2 | 7.94 % | $ 322 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 3.21 | 4.56 % | $ 6.98 B | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
Catalyst Biosciences
CBIO
|
14 M | $ 19.97 | 2.94 % | $ 1.78 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Codexis
CDXS
|
-36.5 M | $ 1.97 | 7.97 % | $ 172 M | ||
|
Cerus Corporation
CERS
|
-7.26 M | $ 1.91 | 2.42 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
-241 M | $ 15.4 | 6.72 % | $ 928 M | ||
|
Coherus BioSciences
CHRS
|
-180 M | $ 1.75 | 0.87 % | $ 205 M | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B |